Suchergebnisse

Maybe most characteristic of the TargetFish1 project, which kicked off some five years ago with 30 partners from 10 EU member states, two associated countries (Norway, Israel) and one international cooperation partner country (Chile), has been the close cooperation between research groups and enterprises; more or less equally represented in this large consortium. In this respect, TargetFish has been revolutionary validating by this close cooperation fundamental knowledge for the development of next generation vaccines and different routes of vaccine administration. TargetFish had the ambition to demonstrate market applicability of improved vaccines or new prototype vaccines that would come forward from the project. Via frequent joint meetings of its partners, be it research group or enterprise, TargetFish aimed to drive vaccine development in an industrial applicable way. This could facilitate adoption of new intellectual property and stimulate the presentation of new fish vaccines on the market. The industry forum has been a platform for a continuing validation of the applied potential of the research outcomes. Workshops were organised at the different EAFP meetings to communicate the validation process to those not directly involved with the project but interested in the fish vaccine market. After a kick-off meeting during the EAFP in Tampere, Finland fours years ago and a second meeting at the EAFP in Las Palmas, Spain, two years ago, at the present EAFP in Belfast, Northern Ireland a final meeting was organised. This report is a summary of the 'Industrial Forum workshop' held at the EAFP in Belfast 2017 and provides a short overview of the highlights presented to, and discussed with, those present and interested in DNA vaccine development, policies and laws, production and delivery routes.

TargetFish is a large collaborative project unded by the European Commission under the 7th Framework Programme or Research and Technological Development (FP7) of the European Union (Grant Agreement 311993). The project that will run or 5 years, started in November 2012 and thus is approximately halway. TargetFish brings together a large number of leading European research groups (RTD) that are experts on ęsh pathology and immunology and small-to-medium enterprises (SME) as well as some larger industries rom the Biotech and Veterinary sectors, which all share a common interest and experience: vaccination of fish.

TargetFish is a large collaborative project funded by the European Commission under the 7th Framework Programme for Research and Technological Development (FP7) of the European Union (Grant Agreement 311993). The project will run for 5 years, started in November 2012 and thus is approximately halfway. TargetFish brings together a large number of leading European research groups (RTD) that are experts on fish pathology and immunology and small-to-medium enterprises (SME) as well as some larger industries from the Biotech and Veterinary sectors, which all share a common interest and experience: vaccination of fish. To achieve this challenging task, we brought together approximately 30 partners from 10 EU member states, two associated countries and one International Cooperation Partner Country (Chile). In this large multidisciplinary consortium an approximate equal number of RTD and SME partners cooperate closely while keeping an intensive communication with the vaccine and nutrition industries. The main objectives of the project are to: 1) generate knowledge by studying antigens and adjuvants for different routes of administration while analyzing the underpinning protective immune mechanisms; 2) validate this knowledge with response assays for monitoring vaccine efficacy and safety, including issues associated with DNA vaccines; 3) approach implementation of prototype vaccines shortening the route to exploitation and 4) optimize vaccination strategies in order to obtain maximum protection in different sizes of fish. At present, progress has been made in particular with regard to main objectives 1-3. The vaccine delivery systems under investigation include oral routes of administration using, for example, alginate microencapsulation and MicroMatrixTM technologies. TargetFish also focuses on investigating mucosal vaccination routes and associated immunity and in developing antigens and adjuvants specifically suited for mucosal delivery. Most fish vaccines on the market are delivered by injection, being this a labour-intensive, expensive method that provokes stress in the fish. Mucosal vaccination routes (immersion or oral) would certainly be more desirable.